Phase 3 Readout
MIST: Phase 3 Topline: Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atria
January 1, 2030 · etripamil. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- January 1, 2030
- Company
- Milestone Pharmaceuticals Inc. (MIST)
- Drug
- etripamil
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atria
- Drug
- etripamil
- Indication
- Atrial Fibrillation